Johnson & Johnson and Boston Scientific have also recently made moves to sell their own coronary intravascular lithotripsy ...

Abbott ABT has received the FDA’s investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (“IVL”) system to evaluate the treatment of severe calcification in coronary ...

Abbott (ABT) announced that the U.S. Food and Drug Administration, FDA, has approved an investigational device exemption, IDE, for its Coronary ...

Abbott will be trying its hand in the growing field of intravascular lithotripsy, with a clinical study to examine an unnamed ...

Abbott begins new Intravascular Lithotripsy trial to improve outcomes in patients with coronary artery disease: Abbott Park, Illinois Wednesday, March 26, 2025, 15:00 Hrs [IST] Ab ...

In current European and American revascularization guidelines, RA grafts are now strongly endorsed as the second conduit for ...

The US Food and Drug Administration (FDA) has granted Abbott an investigational device exemption to evaluate the company’s ...

Abbott (NYSE: ABT) received FDA investigational device exemption (IDE) approval for its coronary intravascular lithotripsy ...

Abbott Laboratories (NYSE:ABT) has caught investor attention with the FDA’s approval of an Investigational Device Exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System, a significant ...

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System to ...

Coronary Artery Disease (CAD) is the most common heart disease and most frequent cause of death in the U.S., with over 20 million adults affected by this condition Abbott's investigational ...